Germo Gericke, Ariceum Therapeutics, tells DDW's Megan Thomas about his work in radiopharmaceuticals for the treatment of cancer and offers valuable advice to others in this field. 1. Where do you work, and can you tell us what you’re working on at the moment? I am the Chief Medical Officer… Read More
Eli Lilly has announced positive results of the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer’s Disease… Read More
Global health science solutions company Revvity, PerkinElmer’s Life Science and Diagnostics business’ new name and branding, has announced the establishment of a Scientific Centre of Excellence in Cambridge, UK. Focused on driving genomic insights to accelerate therapeutic discovery, Revvity’s Scientific Centre of… Read More
ICON, a healthcare intelligence and clinical research organisation, recently released its ICON Cares 2022 Environmental, Social and Governance (ESG) Report. Diarmaid Cunningham, Chief Administrative Officer at ICON, shares insight with DDW. At ICON, we engage with our key stakeholders through a variety of methods and the environmental, social and governance… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Despite the bad news for the UK life sciences industry this week that international investment dropped… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Despite the bad news for the UK life sciences industry this week that international investment dropped… Read More
Calliditas Therapeutics has announced interim data from a proof-of-concept Phase II trial in patients with squamous cell carcinoma of the head and neck (SCCHN) with its lead NOX 1 and 4 inhibitor product candidate, setanaxib. The analysis reflects encouraging early clinical progression-free survival (PFS) results and… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with… Read More
Recursion, a clinical stage company decoding biology to industrialise drug discovery, has announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE). Recursion also announced plans to accelerate development of its AI foundation models for biology and chemistry,… Read More
In this listicle, Thermo Fisher Scientific outlines three problems solved by the Thermo Fisher Connect Platform Team Edition and below, they expand to five reasons why companies should consider this platform. How do you secure your data? How do you share instruments? The Thermo Fisher Connect Platform Team… Read More
In this listicle, Thermo Fisher Scientific outlines three problems solved by the Thermo Fisher Connect Platform Team Edition and below, they expand to five reasons why companies should consider this platform. How do you secure your data? How do you share instruments? The Thermo Fisher Connect Platform Team… Read More
UK technology company FourPlus, along with collaborators Holosphere and the Cell and Gene Therapy Catapult, have been awarded funding from Innovate UK to create and test a mixed reality training platform that enables customised training delivery for pharmaceutical companies and healthcare. The project is a £1… Read More
Sequana Medical, a company targeting fluid overload in liver disease, heart failure and cancer, has enrolled the first patient in its MOJAVE study. MOJAVE, a randomised controlled Phase I/IIa study in the US, will evaluate the safety and efficacy of the company’s second-generation DSR product (DSR 2.0)… Read More
Pheon Therapeutics, an antibody drug conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, has entered an exclusive licence agreement with Biocytogen Pharmaceuticals, a global biotech company focused on the discovery of novel antibody therapeutics. Under the terms of the agreement, Pheon… Read More
DDW has published the latest addition to its Guide Series, ‘Where is the innovation and opportunity in the therapeutic antibody market and how is it evolving?’ It is sponsored by Bio-Rad Laboratories. In this free, exclusive guide, you will read: The future of therapeutic… Read More
